Agios Pharmaceuticals Insider Sells $102,047 in Stock
Agios Pharmaceuticals insider Sarah Gheuens sold 2,940 shares of the company's stock for $102,047 to cover tax obligations related to equity awards. This routine transaction, executed under a pre-arranged Rule 10b5-1 trading plan, reduced her position by 3.53%. Such sales are generally considered neutral by investors as they do not indicate a negative outlook on the company's prospects.
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $113,224.02 in Stock
Agios Pharmaceuticals insider Tsveta Milanova sold 3,262 shares of stock for $113,224.02 on April 2nd, 2026, reducing her holdings by 6.51%. The sale was conducted under a Rule 10b5-1 trading plan to cover tax obligations from vested equity awards. The company currently holds a "Hold" consensus rating from analysts with an average price target of $42.67, despite some recent price target increases from various firms.
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Cecilia Jones Sells 3,141 Shares
Agios Pharmaceuticals CFO Cecilia Jones sold 3,141 shares of AGIO stock for $109,024 to cover tax withholdings from vested equity. This transaction, executed under a Rule 10b5-1 plan, reduced her stake by 5.40% to 54,998 shares. The biopharmaceutical company's stock traded down 1.1% to $34.80 on above-average volume, with a current market cap of $2.04 billion.
Agios Pharmaceuticals Insider Sells $102K in Shares
An insider at Agios Pharmaceuticals, Sarah Gheuens, sold 2,940 shares worth $102,047.40 on April 2nd, 2026. This transaction reduced her ownership stake by 3.53% and was executed under a Rule 10b5-1 plan to cover tax obligations from vested equity awards. The sale provides investors with insight into management's outlook on the company, which specializes in cancer and rare genetic disease treatments.
AGIO: JP Morgan Raises Price Target to $36, Maintains Neutral Rating
JP Morgan has raised its price target for Agios Pharmaceuticals (AGIO) from $31.00 to $36.00, a 16.13% increase, while maintaining a Neutral rating. This follows several other analyst updates, with the average target price from 7 analysts being $43.00, implying a 23.21% upside from the current price. GuruFocus estimates a one-year fair value (GF Value) of $150.63 for AGIO, suggesting a significantly higher upside.
Jones Cecilia, Agios Pharmaceuticals CFO, sells $109k in stock
Agios Pharmaceuticals CFO, Cecilia Jones, sold 3,141 shares of common stock totaling $109,024 to cover tax obligations related to vested performance share units. This transaction occurred after the stock saw a nearly 19% surge and was part of a pre-arranged trading plan. In separate news, Agios Pharmaceuticals is pursuing U.S. accelerated approval for its drug mitapivat for sickle cell disease, with analysts raising price targets due to increased confidence in its approval path.
Jones Cecilia, Agios Pharmaceuticals CFO, sells $109k in stock
Agios Pharmaceuticals CFO, Cecilia Jones, sold 3,141 shares of common stock worth $109,024 to cover tax obligations related to vested performance share units. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, Jones exercised options for 8,500 shares and still directly owns 54,998 shares, as the company stock has gained nearly 19% recently and is considered undervalued.
[Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity
AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Sarah Gheuens exercised 8,500 performance share units after a regulatory milestone was met on April 2, 2026. Following this, she sold 2,940 shares of common stock at $34.71 per share to cover tax withholding obligations, as per pre-set instructions. After these transactions, Gheuens directly owns 80,277 common shares, including shares from the company's employee stock purchase plan.
Agios (NASDAQ: AGIO) exec sells shares to cover PSU tax obligations
Agios Pharmaceuticals executive Krishnan Viswanadhan sold 2,959 shares of the company's common stock at $34.71 per share to cover tax withholding obligations after 8,100 performance share units (PSUs) vested. The vesting occurred on April 2, 2026, when a specified regulatory milestone was achieved, converting the PSUs into common stock. This transaction was conducted under pre-planned Rule 10b5-1(c) instructions, and after the sale, Viswanadhan directly holds 10,282 shares of Agios common stock.
JPMorgan Chase & Co. Raises Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $36.00
JPMorgan Chase & Co. has increased its price target for Agios Pharmaceuticals (NASDAQ:AGIO) from $31.00 to $36.00, maintaining a "neutral" rating. This adjustment implies a potential upside of 3.78% from the stock's previous close. Other analysts have also raised their price targets, contributing to a consensus "Hold" rating for AGIO with an average target of $42.67.
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced it will host a conference call and live webcast on April 29, 2026, at 8:00 a.m. ET to report its first-quarter 2026 financial results and business highlights. The event will be accessible via the Investors section of the company’s website. Agios, a commercial-stage biopharmaceutical company, focuses on developing medicines for rare diseases.
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Announces Target Price $36
J.P. Morgan has reiterated its Hold rating on Agios Pharmaceuticals (AGIO.US) and set a target price of $36. This announcement provides investors with an analyst's perspective on the company's valuation and investment potential.
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
Agios Pharmaceuticals, Inc. announced it will host a conference call and live webcast on April 29, 2026, at 8:00 a.m. ET to discuss its first quarter 2026 financial results and business highlights. The webcast will be accessible on the Investors section of the company’s website, with a replay available shortly after the event. Agios, a biopharmaceutical company focused on rare diseases, uses its website and other channels to disseminate information, including material disclosures.
A Look At Agios Pharmaceuticals (AGIO) Valuation As It Pursues Accelerated FDA Approval For Mitapivat
Agios Pharmaceuticals (AGIO) is seeking accelerated FDA approval for mitapivat in sickle cell disease, leading to recent share price gains. Despite a 5-year decline, the stock has seen a 61.69% return over three years and 36.65% in the past year. The article explores AGIO's valuation, noting its "undervalued" status based on analyst targets but also highlights valuation risks due to its high P/S ratio compared to industry peers.
AGIO SEC Filings - Agios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms
This page provides access to Agios Pharmaceuticals Inc.'s SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents, enhanced with AI-powered summaries. Recent filings detail insider transactions by multiple directors, reporting new equity grants of restricted stock units and stock options, and the conversion of previously granted RSUs into common shares. An S-8 filing also registered additional shares for an amended equity plan, facilitating future compensation.
AGIO Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for AGIO, detailing past quarterly results and future forecasts. It highlights analyst expectations for 2026/Q1, including projected revenue and EPS, and discusses the correlation between earnings revisions and stock price movements. The report also offers insights into historical stock price reactions around earnings releases, suggesting potential buying opportunities based on long-term fundamentals and strategic initiatives.
AGIO (NASDAQ: AGIO) affiliate files to sell 2,940 shares after RSU vesting
AGIO Pharmaceuticals filed a Form 144 notice for a proposed sale of 2,940 shares of common stock, stemming from the vesting of Restricted Stock Units on April 2, 2026. The filing also disclosed a prior sale of 4,055 shares on March 2, 2026. This is identified as a routine affiliate sale through Morgan Stanley Smith Barney LLC.
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing
AGIOS PHARMACEUTICALS, INC. (AGIO) reported a Form 144 SEC filing detailing the sale and transfer of executive restricted stock units. The filing indicates the vesting of 19,068 RSU shares on April 2, 2026, and a prior sale of 18,055 shares on March 2, 2026, for $522,873. A securities compliance lawyer characterized the filing as a neutral, routine disclosure of Rule 144 resale and RSU vesting.
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Agios Pharmaceuticals (AGIO) saw a 14.3% jump in share price after announcing its intention to seek accelerated FDA approval for its lead drug, mitapivat, for sickle cell disease. The company is actively engaging with the FDA regarding the confirmatory study design and plans to submit the supplemental new drug application in the coming months. Despite an expected quarterly loss, higher earnings estimate revisions suggest potential continued strength for the stock.
AGIO Shares Climb as Mitapivat Advances Toward Fast-Track Approval for SCD
Agios Pharmaceuticals (AGIO) shares surged by 14% after the company announced its plan to seek fast-track FDA approval for its drug mitapivat to treat sickle cell disease (SCD). This decision was based on positive Phase II and III clinical trial results and discussions with the FDA, which recommended a confirmatory study. Mitapivat is already approved under different names for other conditions, and AGIO intends to file a supplemental new drug application (sNDA) soon.
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
Agios Pharmaceuticals (AGIO) shares surged 14% after the company announced its intent to seek accelerated FDA approval for mitapivat in treating sickle cell disease (SCD). Despite the phase III RISE UP study not achieving statistical significance for pain crises reduction, it met the primary endpoint for hemoglobin response and key secondary endpoints. AGIO plans to submit a supplemental New Drug Application (sNDA) soon, following FDA guidance to propose a confirmatory clinical study to support the accelerated approval pathway.
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Levi & Korsinsky has launched an investigation into Agios Pharmaceuticals, Inc. (AGIO) regarding potential federal securities law violations. This follows Agios' announcement on November 19, 2025, that its RISE UP Phase 3 trial for Mitapivat in Sickle Cell Disease met one primary endpoint but failed another, and a key secondary endpoint. Consequently, Agios' stock price dropped significantly.
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Levi & Korsinsky has launched an investigation into Agios Pharmaceuticals, Inc. (AGIO) following potential violations of federal securities laws. This comes after the company's RISE UP Phase 3 trial for Mitapivat in Sickle Cell Disease failed to meet a key secondary endpoint, leading to a significant drop in stock price. Investors who lost money are encouraged to contact the firm for more information.
Why Agios Pharmaceuticals (AGIO) Is Up 5.3% After FDA Opens Door To Accelerated Mitapivat Filing
Agios Pharmaceuticals saw a 5.3% increase after the FDA indicated openness to an accelerated approval for mitapivat in sickle cell disease, prompting the company to pursue this path. While this creates a potential near-term regulatory catalyst and strengthens the mitapivat franchise alongside its recent approval for thalassemia, it also highlights the company's reliance on this single drug platform, presenting a concentration risk for investors. Analysts view this development with varied optimism, some expecting higher revenue, while others caution about the risks associated with a narrow pipeline and ongoing losses.
Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon?
Agios Pharmaceuticals (NASDAQ:AGIO) stock surged over 20% on Tuesday after the company announced its intention to pursue accelerated FDA approval for mitapivat in treating sickle cell disease. This decision follows a positive pre-supplemental New Drug Application meeting with the FDA, where the agency recommended submitting a confirmatory clinical trial proposal. Data from the RISE UP clinical program, including Phase 3 studies, showed statistical significance in hemoglobin response for mitapivat, boosting investor confidence despite the drug not meeting statistical significance for reducing pain crises.
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money
The Gross Law Firm has announced an investigation into potential securities fraud claims against Agios Pharmaceuticals, Inc. on behalf of shareholders who have incurred losses. The firm, a nationally recognized class action law firm, is committed to protecting investors from deceitful business practices and recouping losses resulting from false or misleading company statements. Shareholders who lost money on their AGIO investment are encouraged to contact The Gross Law Firm to discuss their rights.
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today
Agios Pharmaceuticals' stock surged over 21% after the company announced its mitapivat drug for sickle cell disease is on an accelerated path to FDA approval. The FDA has approved a proposal for a confirmatory clinical trial, potentially speeding up market availability for this "multi-purpose therapy." While the stock remains volatile, its potential to address an underserved market experiencing significant growth suggests further upside for risk-tolerant investors.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Hold" from Analysts
Agios Pharmaceuticals (NASDAQ:AGIO) has received an average "Hold" rating from eleven analysts, with one sell, four hold, and six buy ratings, alongside an average 12-month target price of $40.67. Recent analyst reports have seen several firms raise their price targets, indicating a generally positive outlook. However, there have been insider sales, with Krishnan Viswanadhan and Tsveta Milanova selling a combined total of over 5,800 shares, reducing total insider ownership to approximately 4.93%.
(AGIO) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily analyzes Agios Pharmaceuticals Inc. (NASDAQ: AGIO) using AI models to generate trading strategies. It highlights a strong near-term sentiment but a neutral mid and long-term outlook, identifying a short setup with a significant risk-reward ratio. The analysis provides specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging strategies.
Agios Pharmaceuticals stock declines 23% in 6 months: Here's why
The article describes a previous market summary for Agios Pharmaceuticals (AGIO) which saw its stock decline by 23.3% in a six-month period, underperforming the S&P 500. This drop is attributed to the inherent volatility and risks associated with clinical-stage biotechnology companies, including the potential for trial failures, regulatory hurdles, and intense market competition. Investors are cautioned about these risks in the biotech sector.
Vanguard (NYSE: V) disaggregates Agios holdings; reports 0% ownership
Vanguard Group filed an amended Schedule 13G/A, reporting zero beneficial ownership of Agios Pharmaceuticals Inc. common stock as of March 13, 2026. This change is due to an internal realignment effective January 12, 2026, which disaggregated beneficial ownership among Vanguard subsidiaries, not because of a market transaction. The filing indicates that certain Vanguard subsidiaries will now report beneficial ownership separately, consistent with SEC Release No. 34-39538.
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation
Levi & Korsinsky has initiated an investigation into Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) for potential federal securities law violations. This investigation follows the company's disclosure on November 19, 2025, that its RISE UP Phase 3 trial for Mitapivat in Sickle Cell Disease met one primary endpoint but failed another, and a key secondary endpoint was also not met. Following this news, Agios's stock price significantly dropped.
AGEOUS STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation
Levi & Korsinsky has initiated an investigation into Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) for potential federal securities law violations. This follows Agios' announcement on November 19, 2025, of mixed results from its RISE UP Phase 3 trial for Mitapivat in Sickle Cell Disease, which failed to meet a key secondary endpoint. After this news, Agios's stock price dropped significantly by $22.33 per share.
Agios Pharmaceuticals stock declines 23% in 6 months: Here's why
This article explains the reasons behind the 23% decline in Agios Pharmaceuticals (AGIO) stock over the past six months, despite a slight gain in the last four weeks. The company's stock underperformed its sector due to significant R&D expenses and a clinical hold on its lead pipeline candidate, vorasidenib. The article also touches upon the company's financial performance and analyst sentiment.
The Gross Law Firm Announces an Investigation on Behalf of Agios Pharmaceuticals, Inc. (AGIO) Shareholders Who May Have Been Affected by Fraud
The Gross Law Firm has initiated an investigation into potential securities fraud claims against Agios Pharmaceuticals, Inc. for investors who may have suffered losses. The firm, a national class action law firm, is committed to protecting investor rights against deceitful business practices and seeking recovery for those affected by false or misleading statements. Shareholders who incurred losses on their AGIO investment are encouraged to contact the firm to discuss their rights.
AGIO Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of Agios Pharmaceuticals Inc (AGIO), detailing its revenue breakdown, profitability margins, and a comparison with competitors INVA and VCEL. AGIO maintains a high gross margin of 90.59% but reports negative operating and net margins, indicating challenges in overall profitability. The company's market capitalization is $1.63 billion, positioning it as a significant player in its sector.
Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded to "Hold" at Wall Street Zen
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by Wall Street Zen from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating and a target price of $40.67. Despite the upgrade, the company currently has a negative P/E ratio, reflecting a lack of profitability, and insiders have been net sellers of the stock. Institutional investors have, however, increased their holdings in the biopharmaceutical company.
AGIO PE Ratio & Valuation, Is AGIO Overvalued
Agios Pharmaceuticals Inc (AGIO) is currently considered undervalued, with its fair price estimated between $32.76 and $51.34 compared to its current price of $27.86. Despite a high P/S ratio compared to competitors, its robust revenue growth of 86.09% may sustain this premium. The article provides various valuation metrics including P/B, FCF Yield, Forward P/E, and Forward P/S ratios as of March 22, 2026.
Agios falls as Leerink cites deaths linked to lead asset Pyrukynd
Agios Pharmaceuticals' stock declined after Leerink highlighted two patient deaths in clinical trials for its lead asset, Pyrukynd (mitapivat). The deaths were attributed to cardiac arrest and complications from sickle cell disease, with Leerink suggesting a possible, though unconfirmed, link to the drug's mechanism of action. This cautionary note from Leerink contributed to the negative market reaction for Agios.
Agios Pharmaceuticals (AGIO) reports Q4 loss, beats revenue estimates
Agios Pharmaceuticals (AGIO) reported a Q4 loss, but exceeded revenue estimates. This suggests that while the company's profitability is still a concern, its sales performance was stronger than anticipated by analysts. Investors will likely be watching how these factors impact future stock performance.
Agios Pharmaceuticals (AGIO) reports Q4 loss, beats revenue estimates
Agios Pharmaceuticals (AGIO) reported a Q4 loss of $1.50 per share, which is wider than its loss of $1.46 per share in the same period last year. Despite the loss, the company surpassed revenue expectations, bringing in $83.58 million compared to the estimated $74 million. This indicates some positive performance in sales despite overall unprofitability for the quarter.
Sickle Cell Disease Market: Investment-Ready Growth Trends to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis
The Sickle Cell Disease (SCD) market, valued at approximately USD 650 million in 2023, is projected to grow significantly by 2034, driven by rising prevalence, increased awareness, and advancements in gene therapy. Key players like BRL Medicine, GlaxoSmithKline, and Vertex Pharmaceuticals are developing novel therapies, with CASGEVY and LYFGENIA anticipated to become market leaders. Despite high treatment costs and accessibility issues in low-income regions, the market is seeing a surge in R&D and clinical trials for new treatments.
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why
Agios Pharmaceuticals' stock has dropped 23% in six months due to mixed phase III data for mitapivat in sickle cell disease and a regulatory delay for its thalassemia indication. While the FDA has since approved mitapivat for thalassemia, investor confidence was impacted by the initial setbacks. The company's future stock performance will depend on the commercial uptake of mitigapivat for thalassemia.
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Levi & Korsinsky, LLP has launched an investigation into Agios Pharmaceuticals, Inc. following a significant drop in its stock price. This comes after the company's RISE UP Phase 3 trial for Mitapivat in Sickle Cell Disease failed to meet a key secondary endpoint and only partially succeeded on primary endpoints. Investors who incurred losses are encouraged to contact Levi & Korsinsky for more information regarding potential violations of federal securities laws.
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Levi & Korsinsky has launched an investigation into Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) for potential violations of federal securities laws. This follows a significant drop in stock price after the company announced mixed results from its RISE UP Phase 3 trial for Mitapivat in Sickle Cell Disease, failing to meet a key secondary endpoint for annualized pain rate and PROMIS Fatigue. Investors who incurred losses are encouraged to contact the firm for more information regarding this ongoing investigation.
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation
The Gross Law Firm is investigating potential securities fraud claims on behalf of investors who incurred losses while investing in Agios Pharmaceuticals, Inc. (AGIO). The firm encourages affected shareholders to contact them to discuss their legal rights. This action is part of their mission to protect investors from deceit, fraud, and illegal business practices that lead to artificial inflation of stock prices.
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation
The Gross Law Firm is investigating potential securities fraud claims on behalf of investors who lost money on Agios Pharmaceuticals, Inc. (AGIO). The firm encouragesAffected AGIO investors to contact them to discuss their legal rights. The Gross Law Firm specializes in class action lawsuits to protect investors from deceit, fraud, and illegal business practices that lead to artificial inflation of stock prices.
AGIO SEC Filings - Agios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Agios Pharmaceuticals Inc. (AGIO) SEC filings, including annual 10-K and quarterly 10-Q reports, material event 8-K forms, and insider trading disclosures. The platform offers AI-powered summaries to simplify complex sections and provides real-time updates for new filings. Recent filings include a Form 3 for beneficial ownership, details on a new director appointment with compensation, a 13G filing revealing Bellevue Group's stake, and several insider trading activities related to executive stock awards triggered by research milestones.
Liquidity Mapping Around (AGIO) Price Events
This article provides an AI-driven liquidity mapping analysis for Agios Pharmaceuticals Inc. (AGIO), indicating a neutral near-term sentiment that could moderate mid-term weakness. It highlights an exceptional risk-reward short setup and outlines three trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal data with support and resistance levels.
Does UAE Thalassemia Approval for PYRUKYND Reframe the Bull Case for Agios Pharmaceuticals (AGIO)?
Agios Pharmaceuticals announced that its drug PYRUKYND (mitapivat) received approval in the UAE for adult patients with alpha- or beta-thalassemia, both non-transfusion-dependent and transfusion-dependent. This approval, facilitated through its partnership with NewBridge Pharmaceuticals, expands Agios's presence in rare hematologic diseases in the Gulf region. While this strengthens the international outlook for the drug, the company's investment narrative still hinges significantly on its upcoming US thalassemia launch and ongoing safety monitoring related to hepatocellular injury.
